C12Y 304/17023
Angiotensin-converting enzyme 2
Official title: Angiotensin-converting enzyme 2 (3.4.17.23)
C12Y304/17023 (Angiotensin-converting enzyme 2) appears on 43 US grants and 180 published applications in this corpus.
Search patents in C12Y- Granted patents
- 43
- Published applications
- 180
- Assignees
- 122
- Inventors
- 502
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 2 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 1 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 0 | 2 |
| 2019 | 2 | 1 |
| 2020 | 1 | 3 |
| 2021 | 4 | 17 |
| 2022 | 7 | 22 |
| 2023 | 6 | 61 |
| 2024 | 7 | 36 |
| 2025 | 9 | 24 |
| 2026 | 5 | 9 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Non-human animals comprising a humanized ACE2 locus11 Aug 2026US 12,702,122 B2Regeneron Pharmaceuticals, Inc.
- Soluble ACE2 protein, fusion proteins thereof with an FC domain, and methods of treatment of an ACE2-related disease21 Jul 2026US 12,686,860 B2Huahui Health Ltd.
- ACE2 muteins and methods of using the same7 Jul 2026US 12,674,153 B2Emmune, Inc.
- Method of treating covid-19 infection using superparamagnetic iron oxide nanoparticle19 May 2026US 12,629,392 B2Imam Abdulrahman Bin Faisal University
- Tetrahedral antibodies28 Apr 2026US 12,612,611 B2Biomolecular Holdings LLC
- Humanized ace2-expressing transgenic mouse susceptible to sars-cov-2 virus infection and method for producing same8 Oct 2026US 2026/0305587 A1Seoul National University R&Db Foundation
- Method for treating covid-19 infection in a human subject10 Sep 2026US 2026/0263510 A1Imam Abdulrahman Bin Faisal University
- Novel coronavirus protective nasal spray, and preparation and use thereof20 Aug 2026US 2026/0242763 A1Sichuan Clover Biopharmaceuticals, Inc.
- Ace2 homologous peptide sequences18 Jun 2026US 2026/0167674 A1Bezmialem Vakif Universitesi
- Immunotherapeutic Proteins Comprising an Fc Region Component With a Mutation at Position 42911 Jun 2026US 2026/0158160 A1Macfarlane Burnet Institute for Medical Research and Public Health Limited
Most cited
By later US patents
- SARS-CoV-2 surrogate virus neutralization assay test kit8US 11,112,412 B1National University of Singapore · 2021
- Adenovirus vectors and methods for using adenovirus vectors8US 11,149,286 B1Mayo Foundation for Medical Education and Research · 2021
- Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimental induced ocular disorders5US 10,314,893 B2The Trustees of the University of Pennsylvania · 2019
- SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein binding4US 11,054,429 B1National University of Singapore · 2021
- Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)3US 10,443,049 B2Northwestern University · 2019